EricDavidJacobsenMD

Oncology • Boston, MA

Assistant Professor, Medicine-Brigham & Women's Hospital, Harvard Medical School

Join to view full profile

Dr. Jacobsen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Jacobsen's full profile

Already have an account?

Office
44 Binney St
Dana 1B30 Danafarber Cancer Institute
Boston, MA 02115
Phone+1 617-632-6633

Fax+1 617-632-5168

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2002 - 2005
Johns Hopkins UniversityResidency, Internal Medicine, 1999 - 2002
Uconn School Of MedicineClass of 1999

Certifications & Licensure

FL State Medical License 2022 - Present
MA State Medical License 2003 - 2026
NH State Medical License 2023 - 2025
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation Start of enrollment: 2006 Jun 01
Completed
Not Applicable
Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma Start of enrollment: 2007 Jun 01
Active, not recruiting
Phase 1
Procurement of Follicular B Cell Lymphoma Cells for the Purpose of Possible Use in Future Clinical Trials Start of enrollment: 2007 Jun 01
Completed
Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma Start of enrollment: 2008 Jun 01
Completed
Phase 2
Tandem Auto-Allo Transplant for Lymphoma Start of enrollment: 2010 Aug 01
Completed
Phase 2
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma Start of enrollment: 2011 Aug 01
Completed
Phase 2
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Start of enrollment: 2013 Jan 31
Completed
Phase 3
Clofarabine for Langerhans in Pedi
Withdrawn
Phase 2
Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma Start of enrollment: 2014 Sep 01
Terminated
Phase 2
A Study of Lenalidomide for Adult Histiocyte Disorders Start of enrollment: 2015 Aug 01
Active, not recruiting
Phase 2
Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma Start of enrollment: 2015 Oct 01
Terminated
Phase 2
STOP-CA (Statins TO Prevent the Cardiotoxicity From Anthracyclines) Start of enrollment: 2017 Jan 13
Completed
Phase 2
Minimal Residual Disease in Peripheral T-cell Lymphoma Start of enrollment: 2017 Jul 31
Completed
Pembrolizumab in Neoplasms or Lymphomas Start of enrollment: 2017 Dec 07
Suspended
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

A phase I trial of vaccination with lethally irradiated lymphoma cells admixed with granulocyte-macrophage colony-stimulating factor secreting K562 cells for the treat...
Eric Jacobsen, Ashley Plant, Robert Redd, Philippe Armand, Mikaela McDonough
Leukemia & Lymphoma. 2024-12-01
A real-world comparison of commercial use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma.
Andrew Looka, David A Qualls, Daniel Matthews, Robert A Redd, Christopher Sakellis
Blood Advances. 2024-11-15
Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: Results from PETAL consortium.
Jessy Xinyi Han, Min Jung Koh, Leora Boussi, Mark Sorial, Sean Michael McCabe
Blood Advances. 2024-10-31

Abstracts/Posters

Dose Optimization of Duvelisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Selection of Regimen for the Dose-Expan...
Eric D Jacobsen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Le...
Eric D Jacobsen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma
Eric D Jacobsen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Pha...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Phase II Study of Brentuximab Vedotin Plus Adriamycin and Dacarbazine without Radiation in Non-Bulky Limited Stage Classical Hodgkin Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Raising the Bar in T-Cell Lymphomas
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Join now to see all

Press Mentions

More Than 110 Dana-Farber Affiliated Faculty Named as 2021 Top Doctors in Boston MagazineJanuary 5th, 2021
Dana-Farber & Other Sites Spur New Wave of Clinical Trials of Therapies for T-cell LymphomaNovember 14th, 2019
Experimental Cancer Shot Shows Promise in Human Lymphoma PatientsApril 9th, 2019
Join now to see all